+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression



Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression



Journal of Experimental Medicine 157(3): 1040-1052



Even though mastocytoma P815 often undergoes a nearly complete rejection in syngeneic mice, the tumor cells almost always escape to form progressive tumors. We found that this was not due to the establishment of an immunosuppressed state because genetically marked P815 cells, that were injected in mice where tumor escape was occurring, were readily rejected. An analysis of escaping tumor cell populations with anti-P815 cytolytic T lymphocyte (CTL) clones showed the presence of stable resistant variants. Using antigen-loss variants found in escaping populations or selected in vitro with CTL clones, we were able to define four different tumor-associated antigenic specificities, each recognized by a specific CTL clone. One of these specificities was absent from all escaping tumor cells and another had been lost by some of them.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 043030226

Download citation: RISBibTeXText

PMID: 6187879

DOI: 10.1084/jem.157.3.1040


Related references

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. European Journal of Immunology 12(5): 406-412, 1982

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. Journal of Experimental Medicine 152(5): 1175-1183, 1980

Immunogenic variants obtained by mutagenesis of mouse masto cytoma p 815 6. occasional escape from host rejection due to antigen loss secondary variants. International Journal of Cancer 31(1): 119-124, 1983

Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Immunogenetics 26(3): 178-187, 1987

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Ii. T lymphocyte-mediated cytolysis. Journal of Experimental Medicine 152(5): 1184-1193, 1980

Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815. European Journal of Cancer and Clinical Oncology 19(11): 1529-1537, 1983

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens. European Journal of Immunology 12(11): 905-908, 1982

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. European Journal of Immunology 12(5): 401-406, 1982

Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. Journal of Immunology 162(6): 3534-3540, 1999

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids. Somatic Cell Genetics 9(3): 345-357, 1983

T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. Journal of Experimental Medicine 154(4): 1033-1042, 1981

Surface expression of CD63 antigen (AD1 antigen) in P815 mastocytoma cells by transfected IgE receptors. Biochemical and Biophysical Research Communications 219(3): 740-744, 1996

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proceedings of the National Academy of Sciences of the United States of America 85(7): 2274-2278, 1988

Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells. International Journal of Cancer 134(12): 2841-2852, 2014

Tryptophan 5-monooxygenase from mouse mastocytoma clone P815. Methods in Enzymology 142: 93-96, 1987